Department of Neurosurgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Neurol India. 2023 Mar-Apr;71(Supplement):S189-S197. doi: 10.4103/0028-3886.373638.
Single-session stereotactic radiosurgery (SRS) is a proven and effective treatment modality for various benign, malignant, and functional intra-cranial pathologies. In certain situations, single-fraction SRS is limited because of lesion size and location. Hypo-fractionated gamma knife radiosurgery (hfGKRS) is an alternative approach for such unconventional indications.
To evaluate the feasibility, efficacy, safety, and complication profile of hfGKRS with evaluation of different fractionation schemes and dosing patterns.
The authors prospectively evaluated 202 patients treated with frame-based hfGKRS over a 9-year period. GKRS was administered fractionated because of either a large volume (>14 cc) or an inability to spare neighboring organs at risk from permissible radiation in single-session GKRS. The inter-fraction interval was kept at 24 hours, and the dose calculation was performed with linear quadratic equations. Patients with more than 3 years of clinical and radiological follow-up were included in prospective analysis. At pre-decided follow-up criteria, treatment effects and side effects were documented on objective scales.
A total of 169/202 patients met inclusion criteria. 41% patients received treatment in three fractions, whereas 59% received two-fraction GKRS. Two patients of giant cavernous sinus hemangiomas were treated with 5 Gy in the five-fraction regimen. In patients with more than 3 years of follow-up, the obliteration rate was 88% for complex arteriovenous malformations (AVMs) treated with hfGKRS because of eloquent locations, whereas it was 62% for Spetzler-Martin grade 4-5 AVMs. For non-AVM pathologies (meningiomas, schwannomas, pituitary adenomas, paragangliomas, hypothalamic hamartomas, etc.), the 5-year progression free survival was 95%. Tumor failure was noted in 0.05% patient population. Radiation necrosis developed in 8.1% patients, and radiation-induced brain edema developed in 12% patients. It was resistant to treatment in 4% patients. No patient developed radiation-induced malignancy. Hypo-fractionation did not provide any hearing improvement in giant vestibular schwannomas.
hfGKRS is a valuable standalone treatment option for candidates unsuitable for single-session GKRS. The dosing parameters need to be tailored as per the pathology and neighboring structures. It provides comparable results to single-session GKRS with an acceptable safety and complication profile.
单次立体定向放射外科(SRS)是一种经过验证且有效的治疗各种良性、恶性和功能性颅内病变的方法。在某些情况下,由于病变的大小和位置,单次分割 SRS 受到限制。分次伽玛刀放射外科(hfGKRS)是治疗这种非常规适应症的替代方法。
评估框架式 hfGKRS 的可行性、疗效、安全性和并发症情况,并评估不同分割方案和剂量模式。
作者前瞻性评估了 9 年内接受框架式 hfGKRS 治疗的 202 名患者。由于体积较大(>14cc)或由于单次 GKRS 中允许的辐射无法保护相邻的危险器官,因此对这些患者进行分次放射外科治疗。分割间隔为 24 小时,剂量计算采用线性二次方程。纳入有 3 年以上临床和影像学随访的患者进行前瞻性分析。根据预定的随访标准,在客观量表上记录治疗效果和副作用。
共 202 名患者中有 169 名符合纳入标准。41%的患者接受 3 次分割治疗,59%的患者接受 2 次分割 GKRS。2 例海绵窦巨大海绵状血管瘤患者接受 5 Gy 的 5 次分割治疗。在有 3 年以上随访的患者中,因位置重要而接受 hfGKRS 治疗的复杂动静脉畸形(AVM)的闭塞率为 88%,而 Spetzler-Martin 分级 4-5 的 AVM 为 62%。对于非 AVM 病变(脑膜瘤、神经鞘瘤、垂体腺瘤、副神经节瘤、下丘脑错构瘤等),5 年无进展生存率为 95%。0.05%的患者出现肿瘤进展。8.1%的患者发生放射性坏死,12%的患者发生放射性脑水肿。其中 4%的患者对治疗有抵抗。没有患者发生放射性恶性肿瘤。分次治疗对大型前庭神经鞘瘤的听力改善没有帮助。
对于不适合单次 GKRS 的患者,hfGKRS 是一种有价值的独立治疗选择。需要根据病变和相邻结构调整剂量参数。它提供了与单次 GKRS 相当的结果,具有可接受的安全性和并发症情况。